CasLoc logo
All Cases PTAB Litigations UPC Oppositions

OSI Pharmaceuticals LLC v. Roxane Laboratories Inc.

1:12-cv-01669

Overview

Case Number 1:12-cv-01669
Filing Date 2012-12-07
Status Terminated
Termination Date 2013-09-16
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Roxane Laboratories Inc. Operating Company

Represented By

1 Attorneys Listed

Mary Matterer

ADDRESS EXPIRED / UNKNOWN

Tel: +1 (302) 888-6800
Fax: +1 (302) 571-1750

ADDRESS EXPIRED / UNKNOWN, (302) 888-6800

Pfizer Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Plaintiff

OSI Pharmaceuticals LLC Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Counter Claimant

Genentech Inc Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 3 proceedings
πŸ›οΈ
USPTO PTAB Trials 1 proceeding
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Parallel Proceedings Across Jurisdictions (4 found):
PTAB: 1 U.S. Courts: 3
USPTO PTAB Trial 2016-06-28
IPR2016-01284

Apotex, Inc. et al. v. OSI Pharmaceuticals, LLC et al.

U.S. Continuation Sibling (6900221)
Status: Final Written Decision
U.S. District Court 2015-09-02
1:15-cv-00772

OSI Pharmaceuticals, LLC v. Apotex Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-05-23
1:12-cv-00644

OSI Pharmaceuticals LLC v. Roxane Laboratories INC.

Asserted Patent
Status: DED
U.S. District Court 2012-04-13
1:12-cv-00465

OSI Pharmaceuticals LLC v. Roxane Laboratories Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
USRE41065
Alkynl and azido-substituted 4-anilinoquinazolines
Filed: 2008-02-27
Issued: 2009-12-29
Expired (Term Ended)
Expires: 2018-11-08
US6900221
Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
Filed: 2000-11-09
Issued: 2005-05-31
Expired (Term Ended)
Expires: 2020-11-09
US7087613
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
Filed: 2004-11-18
Issued: 2006-08-08
Expired (Term Ended)
Expires: 2024-11-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked (3.5, 7.5, 11.5 Years).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

2

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 2

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
Joint STIPULATION TO EXTEND TIME Respond to Complaint to March 18, 2013 - filed by Roxane Laboratories Inc.. (Matterer, Mary) (Entered: 02/12/2013)
Entry #7 • 2013-02-12 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendant Roxane Laboratories, Inc. to answer, move, or otherwise respond to the Complaint to February 15, 2013 - filed by Genent...
Entry #6 • 2013-01-07 Document →

Docket Entries

(20 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT - filed with Jury Demand against Roxane Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350.00, receipt number 0311-1186612.) - filed by Pfizer Inc., OSI Pharmaceuticals LLC, Genentech Inc. (Attachments: # 1 Exhibit A - C, # 2 Civil Cover Sheet)(rwc) (Entered: 12/07/2012)

Entry #1 • 2012-12-07
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT - filed with Jury Demand against Roxane Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350.00, receipt number 0311-1186612.) - filed by Pfizer Inc., OSI Pharmaceuticals LLC, Genentech Inc. (Attachments: # 1 Exhibit A - C, # 2 Civil Cover Sheet)(rwc) (Entered: 12/07/2012)

Entry #1 • 2012-12-07
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT - filed with Jury Demand against Roxane Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350.00, receipt number 0311-1186612.) - filed by Pfizer Inc., OSI Pharmaceuticals LLC, Genentech Inc. (Attachments: # 1 Exhibit A - C, # 2 Civil Cover Sheet)(rwc) (Entered: 12/07/2012)

Entry #1 • 2012-12-07
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (rwc) (Entered: 12/07/2012)

Entry #2 • 2012-12-07
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/7/12. Date of Expiration of Patents: 11/8/18, 11/9/20, 11/9/20.Thirty Month Stay Deadline: 5/7/2015. (rwc) (Entered: 12/07/2012)

Entry #3 • 2012-12-07
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc